NCT05158894View on ClinicalTrials.gov

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

RecruitingOBSERVATIONAL
Enrollment

1,884

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

September 30, 2034

Study Completion Date

September 30, 2034

Conditions
Migraine
Trial Locations (1)

27703-8426

RECRUITING

Iqvia /Id# 266904, Durham

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT05158894 - Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy | Biotech Hunter | Biotech Hunter